Claude Strother says he's bagged more than 250 turkeys over the years, but he's received more attention for this one hunt.

J&J submitted a New Drug Application to the FDA for TAR-200 in January 2025 following positive data from the SunRISe-1 trial.

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer ...

Diliman has identified potential biomarkers or signs that can help with early lung cancer detection with the support of the ...

Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and simultaneously published in The New England Journal of ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and ...

According to the International Agency for Research on Cancer, lung cancer is the leading cause of cancer-related deaths ...

Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.